In the post-hoc analysis of intensive care unit with anidulafungin. Interestingly, mean APACHE II score some h Forth in this study, a total of C / IC Bev Lkerung. Patients with APACHE II 5 were excluded GDC-0941 from our study because the high mortality rate in these patients was to assess the efficacy of drugs in patients with an APACHE II score 25 or even 20 are affected, different treatments are no longer detectable. Initially, the exclusion of patients with a high score Highest Likely to Similar reactions have contributed to independent Ngig of the APACHE II score, in contrast to what is observed in some previous studies. The treatment duration was l Longer than in prospective studies evaluating echinocandins for C / IC in the general Bev Lkerung all patient k Patients in the ICU may require L Ngere antifungal therapy than non-patients in the ICU.
Our results suggest that response rates and overall survival in patients were seriously ill at all time points lower than before in a general Bev Lkerung observed. This is consistent with other analyzes show that critically ill patients with invasive Candida infections have an hour Here mortality and poorer outcomes independent Ngig used by the antifungal agent, which are probably the worst condition underlying this part of Bev Lkerung. ICU patients with systemic Candida infections should therefore be the most effective treatment available antifungal agents, most ttm Possible. Because echinocandins can rapidly fungicides positive impact on patient outcomes actionof these agents are now generally regarded as first-line C / CI in m Thirty to seriously ill patients is recommended.
The results of our study confirm to these clinical guidelines. Anidulafungin is the only echinocandin requirements without dose adjustment for renal and liver failure, and with no known drug interactions with other drugs. In our study, patients with limited Nkter liver function and / or kidney failure responds just as well as patients in intensive care total support and the potential value of anidulafungin in patients with organ dysfunction. Although all patients U concomitant medications were new, was the reps Excellent opportunity of anidulafungin. Our study included a significant proportion of C / IC patients with deep infection.
This is considerably larger It than in previous tests echinocandin C / IC, including normal post-hoc analysis of patients in intensive care support, and the efficacy of anidulafungin for the treatment of invasive candidiasis and candid Chemistry. Also note that anidulafungin is as effective against C. parapsilosis than against other species was. This special agent, has a bit on the higher minimum inhibitory concentrations echinocandin other Candida species, although the clinical significance of these findings is unknown. Response to treatment of C. tropicalis was lower than for other Candida species, and also lower than previously reported with anidulafungin for C. tropicalis. However, our Stichprobengr was E small for this subset. The distribution of species was observed, which is a pan-european European and CMI were expecting Similar as previously reported. Our results confirm to the potential usefulness of the Candida score for early diagnosis of the C / HF in patients in intensive care, with notes in the rule h Ago as the previously defined threshold of 2.5. In this study, as